Towards Developing Discriminating Dissolution Methods for Formulations Containing Nano-Particulates in Solution; The Impact of Particle Drift and Drug Activity in Solution.
Sign Up to like & getrecommendations! Published in 2020 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.0c00599
Abstract: Enabling formulations are an attractive approach to increase the dissolution rate, solubility, and oral bioavailability of poorly soluble compounds. With the growing prevalence of poorly-soluble drug compounds in the pharmaceutical pipeline, supersaturating drug delivery systems… read more here.
Keywords: drug; dissolution methods; activity solution; drug activity ... See more keywords
Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00114-22
Abstract: The rate at which parasitemia declines in a host after treatment with an antimalarial drug is a major metric for assessment of antimalarial drug activity in preclinical models and in early clinical trials. However, this… read more here.
Keywords: antimalarial drug; drug activity; parasite viability; activity ... See more keywords
A feature transferring workflow between data-poor compounds in various tasks
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0266088
Abstract: Compound screening by in silico approaches has advantages in identifying high-activity leading compounds and can predict the safety of the drug. A key challenge is that the number of observations of drug activity and toxicity… read more here.
Keywords: activity toxicity; activity; drug activity; data poor ... See more keywords
Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.587377
Abstract: Novel oncology drugs often fail to progress from preclinical experiments to FDA approval. Therefore, determining which preclinical or clinical factors associate with drug activity could accelerate development of effective therapies. We investigated whether preclinical metrics… read more here.
Keywords: phase; drug; cancer; drug activity ... See more keywords